Lotery, Andrew <br/><br/>
Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial.  [electronic resource] 

 -  Lancet (London, England)  01 2020 
 - 294-303 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1474-547X 
<br/><br/><label>Standard No.: </label>10.1016/S0140-6736(19)32981-2  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Central Serous Chorioretinopathy--drug therapy<br/>Chronic Disease<br/>Double-Blind Method<br/>Eplerenone--adverse effects<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Male<br/>Middle Aged<br/>Mineralocorticoid Receptor Antagonists--adverse effects<br/>Treatment Outcome<br/>Visual Acuity--drug effects<br/>Young Adult<br/>Assessment of Medication Adherence